EurointerventionPub Date : 2026-07-20DOI: 10.4244/EIJ-D-26-00421
Bahram Yosofi, Eva C I Woelders, Denise A M Peeters, Clemens von Birgelen, Johannes B van Rees, Antonius A C M Heestermans, Bimmer E P M Claessen, Stijn C H van den Oord, Maurits T Dirksen, Daphne van Vliet, Lara S F Konijnenberg, Aysun Cetinyurek-Yavuz, Niels van Royen, Robert-Jan M van Geuns, Robin Nijveldt, Peter Damman
{"title":"Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial.","authors":"Bahram Yosofi, Eva C I Woelders, Denise A M Peeters, Clemens von Birgelen, Johannes B van Rees, Antonius A C M Heestermans, Bimmer E P M Claessen, Stijn C H van den Oord, Maurits T Dirksen, Daphne van Vliet, Lara S F Konijnenberg, Aysun Cetinyurek-Yavuz, Niels van Royen, Robert-Jan M van Geuns, Robin Nijveldt, Peter Damman","doi":"10.4244/EIJ-D-26-00421","DOIUrl":"10.4244/EIJ-D-26-00421","url":null,"abstract":"<p><strong>Background: </strong>Ticagrelor monotherapy after a short period of dual antiplatelet therapy (DAPT) has been shown to be safe and effective after percutaneous coronary intervention (PCI), including primary PCI for patients with ST-segment elevation myocardial infarction (STEMI). However, the omission of aspirin could further reduce bleeding risk.</p><p><strong>Aims: </strong>We aimed to assess the impact of ticagrelor monotherapy directly after primary PCI in terms of ischaemic events and to investigate the effect on clinical bleeding events.</p><p><strong>Methods: </strong>In this multicentre, open-label pilot study, 200 STEMI patients were randomised 1:1 to ticagrelor monotherapy versus ticagrelor plus aspirin, directly after primary PCI. Major adverse cardiac and cerebrovascular events (MACCE) and bleeding were assessed at 13 months. The incidence of intramyocardial haemorrhage (IMH) was compared between groups.</p><p><strong>Results: </strong>In the ticagrelor monotherapy group (n=98) and DAPT group (n=101), MACCE occurred in 4.1% versus 4.0%, respectively (hazard ratio [HR] 1.04, 95% confidence interval [CI]: 0.26-4.17). Clinically relevant bleeding was observed in 4.1% versus 10.9% (HR 0.37, 95% CI: 0.12-1.17), and clinically relevant non-access site bleeding in 2.0% versus 9.9% (HR 0.20, 95% CI: 0.04-0.92).</p><p><strong>Conclusions: </strong>While no significant difference in ischaemic events was observed between ticagrelor monotherapy and DAPT in the first 13 months after primary PCI, this pilot study was underpowered to confirm efficacy. In addition, non-access site bleeding events were significantly reduced, and there was a downward trend in all clinical bleeding events. The incidence of IMH was similar between groups. (ClinicalTrials.gov: NCT05986968).</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":" ","pages":"e773-e783"},"PeriodicalIF":9.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148037606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EurointerventionPub Date : 2026-07-20DOI: 10.4244/EIJ-D-25-00731
Teresa Bastante, Javier Cuesta, Fernando Alfonso
{"title":"Collapse of a new-generation magnesium scaffold.","authors":"Teresa Bastante, Javier Cuesta, Fernando Alfonso","doi":"10.4244/EIJ-D-25-00731","DOIUrl":"10.4244/EIJ-D-25-00731","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"22 14","pages":"e798-e799"},"PeriodicalIF":9.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EurointerventionPub Date : 2026-07-20DOI: 10.4244/EIJ-D-26-00148
Jacopo Farina, Sant Kumar, Gianluca Campo, Simone Biscaglia, Alberto Sarti, Joan Llevadot-Sesmilo, Valeria Paradies, Gianluca Mincione, Brian Christopher Case, Antonio Maria Leone, Domenico Galante, Andrea Erriquez, Salvatore Brugaletta
{"title":"Endotype-guided medical therapy and symptom response in ANOCA.","authors":"Jacopo Farina, Sant Kumar, Gianluca Campo, Simone Biscaglia, Alberto Sarti, Joan Llevadot-Sesmilo, Valeria Paradies, Gianluca Mincione, Brian Christopher Case, Antonio Maria Leone, Domenico Galante, Andrea Erriquez, Salvatore Brugaletta","doi":"10.4244/EIJ-D-26-00148","DOIUrl":"10.4244/EIJ-D-26-00148","url":null,"abstract":"<p><strong>Background: </strong>Invasive coronary functional testing enables the classification of angina with non-obstructive coronary arteries (ANOCA) into distinct endotypes. However, real-world data linking endotype identification to subsequent pharmacological management and patient-reported symptom outcomes remain limited.</p><p><strong>Aims: </strong>We sought to evaluate the association between coronary endotypes, post-testing pharmacological treatment patterns, and changes in angina-related quality of life in patients with ANOCA in a multicentre real-world registry.</p><p><strong>Methods: </strong>Consecutive ANOCA patients undergoing invasive coronary functional testing were included. Patients were classified into six endotypes using adenosine- and acetylcholine-based testing. Pharmacological therapy was adjusted at the discretion of the treating physician based on the functional test results. The primary endpoint was a clinically meaningful improvement in angina-related health status, defined as a ≥5-point increase in the 7-item Seattle Angina Questionnaire (SAQ-7) summary score, assessed within each endotype.</p><p><strong>Results: </strong>Among 525 patients, endotype distribution was as follows: normal physiology 10.5%, elevated resting coronary blood flow 8.8%, high resistance 13.9%, compensated high resistance 14.9%, epicardial spasm 33.3%, and microvascular spasm 18.7%. After testing, prescription patterns differed across the endotypes, with increased use of beta blockers, ranolazine, and renin-angiotensin-aldosterone system blockers in coronary microvascular dysfunction endotypes and greater use of non-dihydropyridine calcium channel blockers in vasospastic endotypes. At follow-up, a ΔSAQ-7 summary score ≥5 points was observed in elevated resting flow, high-resistance, compensated high-resistance, and epicardial spasm endotypes (all p<0.001) but not in microvascular spasm or normal physiology.</p><p><strong>Conclusions: </strong>In this multicentre real-world registry, invasive coronary endotyping was associated with distinct pharmacological management patterns and differential changes in angina-related quality of life across ANOCA endotypes.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"22 14","pages":"e784-e794"},"PeriodicalIF":9.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EurointerventionPub Date : 2026-07-20DOI: 10.4244/EIJ-D-26-00648
Raffaele Piccolo, Antonio Pio Vitale
{"title":"When less is no longer more: very early aspirin discontinuation after ACS.","authors":"Raffaele Piccolo, Antonio Pio Vitale","doi":"10.4244/EIJ-D-26-00648","DOIUrl":"10.4244/EIJ-D-26-00648","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"22 14","pages":"e757-e759"},"PeriodicalIF":9.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EurointerventionPub Date : 2026-07-20DOI: 10.4244/EIJ-D-25-01215
Caïa Crooijmans, Tijn P J Jansen, Behruz Yosofi, Fleur W Adriaansen, Joan G Meeder, Wouter S Remkes, Marcel A M Beijk, Yolande Appelman, Tim P van de Hoef, Annemiek de Vos, Valeria Paradies, Martijn Meuwissen, Nicola S Vos, Els G M Olde Bijvank, Michael Magro, Stijn C H van den Oord, Karin E Arkenbout, Ton A A C M Heestermans, Marlies M Kok, Pier Woudstra, Melina C den Haan, Patty Winkler, Arnoud van 't Hof, Hester M den Ruijter, Aysun Cetinyurek-Yavuz, Niels van Royen, Suzette Elias-Smale, Aukelien C Dimitriu-Leen, Peter Damman, On Behalf Of The Nl-Cft Investigators
{"title":"Prevalence of vasomotor dysfunction in patients with residual or recurrent angina after percutaneous coronary intervention.","authors":"Caïa Crooijmans, Tijn P J Jansen, Behruz Yosofi, Fleur W Adriaansen, Joan G Meeder, Wouter S Remkes, Marcel A M Beijk, Yolande Appelman, Tim P van de Hoef, Annemiek de Vos, Valeria Paradies, Martijn Meuwissen, Nicola S Vos, Els G M Olde Bijvank, Michael Magro, Stijn C H van den Oord, Karin E Arkenbout, Ton A A C M Heestermans, Marlies M Kok, Pier Woudstra, Melina C den Haan, Patty Winkler, Arnoud van 't Hof, Hester M den Ruijter, Aysun Cetinyurek-Yavuz, Niels van Royen, Suzette Elias-Smale, Aukelien C Dimitriu-Leen, Peter Damman, On Behalf Of The Nl-Cft Investigators","doi":"10.4244/EIJ-D-25-01215","DOIUrl":"10.4244/EIJ-D-25-01215","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"22 14","pages":"e795-e797"},"PeriodicalIF":9.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EurointerventionPub Date : 2026-07-06DOI: 10.4244/EIJ-D-26-00453
Philippe Garot, Jens Erik Nielsen-Kudsk
{"title":"AnchorMan versus Watchman 2.5: a randomised comparison in left atrial appendage closure.","authors":"Philippe Garot, Jens Erik Nielsen-Kudsk","doi":"10.4244/EIJ-D-26-00453","DOIUrl":"10.4244/EIJ-D-26-00453","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"22 13","pages":"e715-e716"},"PeriodicalIF":9.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13330108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EurointerventionPub Date : 2026-07-06DOI: 10.4244/EIJ-D-26-00158
Gregory P Fontana, Ron Waksman, Arash Salemi, Marc Cohen, William Abernethy, James Hermiller, Craig Baker, Joseph Montarello, Neal Kleiman, Lars Sondergaard, Eric Gnall, Roberto Rodriguez, Hemal Gada, William Brinkman, Neil J Weissman, Paul Mahoney, Raj Makkar
{"title":"Prosthesis-patient mismatch with intra-annular self-expanding valves: an analysis of the PORTICO IDE trial.","authors":"Gregory P Fontana, Ron Waksman, Arash Salemi, Marc Cohen, William Abernethy, James Hermiller, Craig Baker, Joseph Montarello, Neal Kleiman, Lars Sondergaard, Eric Gnall, Roberto Rodriguez, Hemal Gada, William Brinkman, Neil J Weissman, Paul Mahoney, Raj Makkar","doi":"10.4244/EIJ-D-26-00158","DOIUrl":"10.4244/EIJ-D-26-00158","url":null,"abstract":"<p><strong>Background: </strong>Aortic valve replacement in small aortic annuli is associated with an increased risk of impaired haemodynamics.</p><p><strong>Aims: </strong>We sought to evaluate haemodynamic outcomes and prosthesis-patient mismatch (PPM) in aortic stenosis (AS) patients treated with Portico, Evolut, and SAPIEN 3 transcatheter aortic valves (TAVs) in small (diameter ≤23 mm) and large (diameter >23 mm) aortic annuli.</p><p><strong>Methods: </strong>PORTICO IDE was a prospective, multicentre, international, premarket randomised controlled trial comparing Portico to Evolut and SAPIEN 3 TAVs. An independent core laboratory evaluated the mean transvalvular pressure gradient (MG) and the effective orifice area (EOA), and PPM was calculated based on the core lab results.</p><p><strong>Results: </strong>A total of 675 patients with severe AS at high or extreme surgical risk were included (Portico: 362 patients; Evolut: 109; SAPIEN 3: 204). At 30 days, the EOA and rates of severe PPM in small aortic annuli were similar between Portico and Evolut (EOA 1.65 cm<sup>2</sup> vs 1.78 cm<sup>2</sup>; p=0.09; PPM 3.3% vs 3.0%; p=1.0) with a higher MG (8.5 mmHg vs 6.9 mmHg; p=0.034) for Portico. No significant differences were observed between Portico and Evolut for large aortic annuli (MG 8.3 mmHg vs 7.4 mmHg; p=0.069; EOA 1.93 cm<sup>2</sup> vs 2.02 cm<sup>2</sup>; p=0.18; PPM 5.4% vs 3.2%; p=0.83). Portico was superior to SAPIEN 3 in both small (MG 8.5 mmHg vs 13.7 mmHg; p<0.0001; EOA 1.65 cm<sup>2</sup> vs 1.40 cm<sup>2</sup>; p<0.0001; PPM 3.3% vs 26.3%; p<0.0001) and large annuli (MG 8.3 mmHg vs 10.9 mmHg; p<0.0001; EOA 1.93 cm<sup>2</sup> vs 1.67 cm<sup>2</sup>; p<0.0001; PPM 5.4% vs 10.9%; p=0.0014). At 5 years, the rate of structural valve deterioration in patients with small aortic annuli was significantly lower in patients treated with Portico (2.2%) versus SAPIEN 3 (13.9%; p=0.03).</p><p><strong>Conclusions: </strong>Haemodynamic performance was similar for the intra-annular Portico and supra-annular Evolut. Portico haemodynamics outperformed the balloon-expandable SAPIEN 3 for PPM and mean gradient in both small and large aortic annuli.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"22 13","pages":"e741-e747"},"PeriodicalIF":9.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13330121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}